No Data
Laekna Successfully Completes Phase I Trial Of Obesity Drug
LAEKNA-B (02105.HK): The Phase I single ascending dose study (SAD study) of LAE102 for the treatment of obesity has been successfully completed.
Gelonghui, January 13 - LAEKNA-B (02105.HK) announced that the group has successfully completed the phase I single ascending dose study ("SAD study") for LAE102 targeting obesity treatment. A total of 64 healthy subjects were recruited for the SAD study, with an average BMI of 23.2±2.2 kg/m2, including 5 intravenous dosing cohorts and 3 subcutaneous dosing cohorts. The results of the SAD study lay the foundation for our upcoming phase I multiple ascending dose study ("MAD study") in China and the phase I clinical study in collaboration with Eli Lilly and Co in the USA.
Laikai Pharmaceutical's self-developed PI3Kα inhibitor was selected for 2024 SABCS and has the best potential in its class
SHANGHAI, December 12, 2024 /PRNewswire/ -- Lai Kai Pharmaceutical (2105.HK) announced today that the company's self-developed result “a variant inhibitor targeting multiple types of PI3Kα mutants — pre-clinical study of LAE118” has been selected for the 2024 San Antonio Breast Cancer Symposium (SABCS) and will present relevant research in the form of a poster at a seminar in San Antonio, Texas, USA on December 13 data. “Very happy to come to Kay
Hong Kong stock concept tracking | Eli Lilly and Co will invest 3 billion USD to expand its production base in the usa, as global demand for weight loss drugs exceeds supply (including concept stocks).
Eli Lilly and Co (LLY.US) will invest 3 billion dollars to expand its production base in the USA.
Laekna Doses All Subjects in LAE102 Phase I Trial
Coming Kai Medicine-B (02105.HK): All subjects have completed dosing in the Phase I single ascending dose study (SAD study) of LAE102 for the treatment of obesity.
On December 4, Gelonghui reported that Comei Pharmaceuticals-B (02105.HK) announced that the Phase I clinical trial of LAE102 is progressing smoothly. As of the date of this announcement, all participants in this Phase I single ascending dose study ("SAD study") have completed administration, including 8 intravenous infusion and subcutaneous injection dose escalation cohorts, totaling 64 participants. Early signs of target binding and expected changes in pharmacodynamic biomarkers have been observed, along with good safety. This Phase I clinical trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the injection of LAE102 in healthy adult participants.
